FINWIRES · TerminalLIVE
FINWIRES

New Zealand Shares Flat; Chorus Fiscal Q4 Fiber Connections Rise to Over 1 Million

By

New Zealand shares were flat with a negative bias on Friday after oil prices spiked as the conflict in the Middle East intensified, raising concerns over inflation.

The S&P/NZX 50 Index was little changed to close at 13,772.29.

Brent crude oil futures were trading over $100 per barrel, after jumping 7% overnight to a two-month high of $102 per barrel. The Iran-aligned Houthis struck Saudi Arabian tankers in the Red Sea even as shipping remains constricted in the Straits of Hormuz.

Meanwhile, the US reportedly plans to impose higher tariffs on goods from 60 trading partners.

In domestic news, Jobs advertisements in New Zealand rose 0.2% month on month in June, extending a 19-month streak of growth, primarily driven by vacancies in the industrial and construction sectors, employment marketplace Seek said.

In corporate news, Chorus (ASX:CNU, NZE:CNU) said fiber connections grew by 5,000 in the fiscal fourth quarter to 1.1 million, compared with a gain of 13,000 in the fiscal third quarter. The company said total fixed line connections fell by 4,000 in the June quarter to 1.2 million, compared with an increase of 3,000 in the previous quarter, as losses in copper connections outpaced gains in fiber connections.

Gentrack Group (ASX:GTK, NZE:GTK) received notice that UBS Group and its affiliated entities decreased their holdings in the company to 5.584% from 6.668.

Related Articles

Asia

Sichuan Biokin Pharmaceutical's ADC Enters Phase Three Trial for Biliary Tract Cancer

Sichuan Biokin Pharmaceutical (SHA:688506) said the first patient for its third-phase randomized controlled clinical trial has been dosed, according to a Friday filing with the Shanghai bourse.The trial is evaluating the company's flagship EGFR×HER3 bispecific antibody drug conjugate (ADC), Lunka Yilong Tuodan/Yizekang, for locally advanced or metastatic biliary tract cancer after platinum chemotherapy failure.Shares of the pharmaceutical company were down 4% in recent trade.

SHA:688506
Asia

Tcm Biotech's Safety Trial for UTI Drug to Continue After Review

Tcm Biotech International (TPE:4169) said an independent review of the interim analysis for its Phase three trial of U101, an oral drug candidate to prevent recurrent urinary tract infections in women, recommended the study continue as planned.The Independent Data Monitoring Committee found the trial's overall safety profile to be sound and recommended continuing patient enrollment, according to a Thursday Taiwan Exchange filing.The company did not disclose efficacy or statistical results, in line with the trial protocol.The trial aims to enroll 348 women, and is assessing U101's ability to prevent recurrent urinary tract infections over a 24-week treatment period.

TPE:4169
Asia

Market Chatter: Indian Billionaire Gautam Adani Considers Entering Airline Business

The group of Gautam Adani is considering launching a new airline, Reuters reported Thursday, citing two sources with direct knowledge of the matter.The report said no final decision has been made, with the group still evaluating the proposal given the challenges of generating profits in the airline industry.The Indian government has privately encouraged several business groups, including Adani, to consider starting an airline as Air India dealt with the aftermath of last year's fatal Ahmedabad crash and IndiGo faced operational disruptions, according to the report.Adani Enterprises (NSE:ADANIENT, BOM:512599), the Indian billionaire's flagship company, did not immediately respond to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

BOM:512599NSE:ADANIENT